top of page
Anchor 1
New About Us Light Blue X Banner Pigs DNA.jpg

About Us

About Us Page Banner V2.jpg

Welcome to XenoTherapeutics, where we're redefining regenerative medicine.


Together, through the shared impact of medical challenges, we are interconnected. Our approach is simple: facilitate the natural repair and replacement of damaged cells and tissues for a healthier future. With a dedicated focus on expediting testing, development, and availability, our goal is to ensure a steady and sufficient supply of regenerative medicine therapies.


Join us in experiencing the future of regenerative medicine

at XenoTherapeutics. Together, let's shape a healthier tomorrow.




Pig Icon.png

Advance the

science of xenotransplantation towards

therapeutic reality.

Handshake Icon.png


with partners, investigators and academic institutions to develop new regenerative medicine therapies.

Heart Icon.png

Lead xenotransplantation to become the

new standard

for regenerative medicine.

Guided by Leaders with the Capacity to Translate Vision into Reality

Comprised of leaders from academia, healthcare, clinical research, and life sciences, our team shares a deep connection and passion for unlocking the potential of regenerative medicine while changing the way new regenerative medicine therapies are discovered and developed.

Dynamic Jon copy.jpg



President & Executive Director

  • 20+ years in medical device and regenerative medicine, with leadership roles at Smith & Nephew, Zimmer Biomet, Bacterin (now Xtant Medical), and Johnson & Johnson.

  • Leads XenoTherapeutics in translating the first skin xenotransplant designated as a Regenerative Medicine Advanced Therapy, providing direct oversight in clinical evaluation, regulatory strategy, intellectual property expansion, and business development.

  • Holds a B.A. from University of Florida and a M.B.A. in Healthcare Management.

Dynamic Jamie copy.jpg


Chief Financial Officer

& Treasurer

  • 20+ years of experience in public and private sector financial management experience in large Pharma and insurance.

  • Oversees and leads XenoTherapeutic’s financial development, core partnerships, and business services functions

  • Former Senior Financial Analyst at Abbott Laboratories.

  • BSc from Indiana University.

Rod Monroy.jpg


Chief Scientific


  • Experienced research scientist in cell therapy R&D, GMP manufacturing, and GCP in the conduct of clinical trials. 

  • Conducted stem cell research in radiation biology and hematopoietic stem cell transplantation. (U.S.Navy)

  • Conducted investigation for the induction of tolerance in xenotransplantation at Biotransplant. 

  • Conducted phase II/III clinical trials using MSCs for the treatment of GVHD (Osiris) and hepatocytes for the treatment of Urea Cycle Disorders (Cytonet). 

  • PhD, Biochemistry, Case Western Reserve University. 

Rob Kaiser Bio XENO Pic.jpg


VP Preclinical Development &

Principal Toxicologist

  • Board-certified toxicologist with 20 years of drug discovery and development experience, contributing to hundreds of INDs over the course of a distinguished career.

  • Shepherds XenoTherapeutics through research and strategic pipeline expansion.

  • Manages academic/biotech collaborations and regulatory affairs, ensuring adherence to all compliance standards for our therapeutics.

  • Co-founder of multiple cell and gene therapy companies, holding a Ph.D. in Biochemistry and completed a research fellowship at Cincinnati Children’s Hospital Medical Center.

Kaitlyn Rogers.jpg


Laboratory Director

  • Over 15 years of diverse experience, including U.S. Marine Corps intelligence, contributing to a seasoned private sector Ops & Marketing Executive role.

  • Leads scientific research at XenoTherapeutics with a focus on converting research into life-improving therapies.

  • Expertise shapes the creation and understanding of new acute therapies for human transplantation.

  • Cum laude graduate in Forensics from American Military University, currently pursuing a Ph.D. in Biochemistry and Molecular Biology at the University of Miami.

New Jessica.jpg


Chief of Staff

  • Over a decade of experience in operations and logistics, including roles as Chief of Staff and COO in a lobbying and media firm.

  • Fosters collaboration and communication among the Board, vendors, partners, and staff, ensuring seamless coordination and effective relationships.

  • Provides essential support for critical projects, ensuring smooth execution and adherence to timelines.

  • Assists the scientific team in data management, contributing to research and development efforts.

Dynamic Dicken copy.jpg


Chief Medical Officer / Clerk

  • Board-certified urologist specializing in renal transplants and general urology.

  • Dr. Ko serves as both Chief Medical Officer and Clerk on the XenoTherapeutics Board of Directors, embodying a unique blend of medical expertise and corporate governance.

  • Former surgical urologist at Massachusetts General Hospital, Boston, with fellowships in multi-organ transplantation and transplantation biology research.

  • Member of the American Board of Urology, the American Society of Transplant Surgeons, and the American College of Surgeons, with a medical degree from Queen’s University School of Medicine, Ontario, Canada.

Mark N. Website.jpg



  • Drug development and CRO veteran with 35+ years of experience.

  • Serves as a Trustee on the XenoTherapeutics Board; began research at MGH, leading H. William Strauss's nuclear cardiology lab.

  • At Centocor, led Preclinical Pharmacology, shaping first-in-class drugs. At Charles River Labs since 1996, held key roles, including establishing a new business unit and growing Biomere into one of the largest specialty contract research labs.

  • Led Biomere through acquisition by Joinn Laboratories, serving as CEO and Executive Steering Committee member. Pharm/tox expertise fuels Celecor's Phase 3 trial for zalunfiban.

Dynamic Bill copy 3.jpg


Board Chairman

  • Senior Vice President - Wealth Management Advisor at Merrill Lynch, PIA Portfolio Manager.

  • Drives innovation on the XenoTherapeutics Board, fostering collaboration through shared expertise and a diverse background.

  • Holds degrees from The Wharton School of the University of Pennsylvania and the University of Massachusetts Amherst.

Ruta J. Laukien Website.jpg



  • Strategic Advisor and Investor focused on strategic advisory in the Global Supply Chain.

  • Brings over 12 years of investment-banking experience, specializing in M&A, debt capital markets, and equity capital raises.

  • Trustee on the XenoTherapeutics Board, safeguards the mission with a focus on responsible and impactful advancements.

  • With seven years at Bear Stearns and as a former Director at C.W. Downer, Laukien contributes Wall Street prowess and deep industry knowledge, specializing in M&A and healthcare transactions.

After three decades of rigorous research in the field of xenotransplantation, pigs have become the preferred source for xenogeneic transplants. We believe these pigs have big potential; when unlocked, they will provide a cure for every single person.

bottom of page